Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 1, 2012, Pages 88-96

  Bambico, Francis Rodriguez ^a   Hattan, Patrick R ^a   Garant, Jean Philippe ^a   Gobbi, Gabriella ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Behavioral despair; Cannabinoids; CB1 receptor; Delta 9 THC; Serotonin

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL; RIMONABANT; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; COPING BEHAVIOR; DORSAL RAPHE NUCLEUS; FORCED SWIMMING TEST; HIPPOCAMPAL CA3 REGION; MALE; NERVE CELL EXCITABILITY; NERVE CELL INHIBITION; NEUROMODULATION; NONHUMAN; RAT; SEROTONINERGIC NERVE CELL; SEROTONINERGIC TRANSMISSION;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; BEHAVIOR, ANIMAL; HIPPOCAMPUS; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONERGIC NEURONS; SYNAPTIC TRANSMISSION; TETRAHYDROCANNABINOL;

EID: 84862896401     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.02.006     Document Type: Article

References (78)

1. Adamczyk P., Golda A., McCreary A.C., Filip M., Przegaliński E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008, 59(2):217-228.
2. Allers K.A., Sharp T. Neurochemical and anatomical identification of fast- and slow-firing neurones in the rat dorsal raphe nucleus using juxtacellular labelling methods in vivo. Neuroscience 2003, 122:193-204.
3. Aso E., Ozaita A., Valdizán E.M., Ledent C., Pazos A., Maldonado R., et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008, 105(2):565-572.
4. Bambico F.R., Gobbi G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets 2008, 12(11):1347-1366.
5. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711.
6. Bambico F.R., Hattan P.R., Katz N., Gobbi G. Differences between fatty acid amide (FAAH inhibitors) and CB1 agonists on the modulation of antidepressant-like behaviour and serotonergic neurotransmission. 38th Annual Meeting 2008, Society for Neuroscience, Washington, D.C., USA, November 15-19.
7. Bambico F.R., Duranti A., Tontini A., Tarzia G., Gobbi G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 2009, 15:1623-1646.
8. Bambico F.R., Nguyen N.T., Gobbi G. Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress. Eur Neuropsychopharmacol 2009, 19:215-228.
9. Bambico F.R., Cassano T., Dominguez-Lopez S., Katz N., Walker C.D., Piomelli D., et al. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 2010, 35(10):2083-2100.
10. Bambico F.R., Nguyen N.T., Katz N., Gobbi G. Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. Neurobiol Dis 2010, 37(3):641-655.
11. Besson A., Haddjeri N., Blier P., de Montigny C. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000, 10:177-188.
12. Beyer C.E., Dwyer J.M., Piesla M.J., Platt B.J., Shen R., Rahman Z., et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010, 39(2):148-155.
13. Blokland A., Lieben C., Deutz N.E.P. Anxiogenic and depressive-like effects, but no cognitive deficits, after repeated moderate tryptophan depletion in the rat. J Pharmacol 2002, 16:39-49.
14. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007, 62(10):1103-1110.
15. Braida D., Limonta V., Malabarba L., Zani A., Sala M. 5-HT1A receptors are involved in the anxiolytic effect of delta9-tetrahydrocannabinol and AM404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007, 555(2-3):156-163.
16. Butovsky E., Juknat A., Goncharov I., Elbaz J., Eilam R., Zangen A., et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to delta-tetrahydrocannabinol. J Neurochem 2005, 93:802-811.
17. Cassano T., Gaetani S., Macheda T., Laconca L., Romano A., Morgese M.G., et al. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. Psychopharmacology 2011, 214(2):465-476.
18. Dahlström A., Fuxe K. Evidence for existence of monoamine-containing neurons in central nervous system - demonstration of monoamines in cell bodies of brain stem neurons. Acta Physiol Scand 1964, (Suppl. 232):1-55.
19. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 2003, 23:2371-2382.
20. Descarries L., Watkins K.C., Garcia S., Beaudet A. The serotonin neurons in nucleus raphe dorsalis of adult rat - a light and electron microscope autoradiographic study. J Comp Neurol 1982, 207:239-254.
21. Egashira N., Mishima K., Katsurabayashi S., Yoshitake T., Matsumoto Y., Ishida J., et al. Involvement of 5-hydroxytryptamine neuronal system in delta(9)-tetrahydrocannabinol-induced impairment of spatial memory. Eur J Pharmacol 2002, 445(3):221-229.
22. Egashira N., Matsuda T., Koushi E., Higashihara F., Mishima K., Chidori S., et al. Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system. Eur J Pharmacol 2008, 589(1-3):117-121.
23. Egertova M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 1998, 265:2081-2085.
24. El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010, 95(4):434-442.
25. ElBatsh M., Spicer C., Marsden C., Fone K., Kendall D. Antidepressant-like effects of chronic cannabinoid agonist and antagonist treatments in the olfactory bulbectomy model of depression in rats. Proceedings of the British Pharmacological Society 2009, Abstract.
26. Esteban S., García-Sevilla J.A. Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, Available online 23 November 2011.
27. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997, 8(3):649-652.
28. García-Gutiérrez M.S., Pérez-Ortiz J.M., Gutiérrez-Adán A., Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010, 160(7):1773-1784.
29. Gobbi G., Murphy D.L., Lesch K.P., Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 2001, 296:987-995.
30. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 2005, 102:18620-18625.
31. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071(1):10-23.
32. Guiard B.P., El Mansari M., Merali Z., Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 2008, 11(5):625-639.
33. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998, 18:10150-10156.
34. Haller J., Mátyás F., Soproni K., Varga B., Barsy B., Németh B., et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007, 25(8):2445-2456.
35. Häring M., Marsicano G., Lutz B., Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007, 146:1212-1219.
36. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009, 71:283-306.
37. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15(6):593-599.
38. Hoffman A.F., Macgill A.M., Smith D., Oz M., Lupica C.R. Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci 2005, 22:2387-2391.
39. Holmes A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 2008, 32:1293-1314.
40. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001, 58(4):322-328.
41. Hungund B.L., Basavarajappa B.S. Distinct differences in the cannabinoid receptor binding in the brain of C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. J Neurosci Res 2000, 60(1):122-128. 1.
42. Jentsch J.D., Andrusiak E., Tran A., Bowers M.B., Roth R.H. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997, 16(6):426-432.
43. Johnson K.M., Dewey W.L., Harris L.S. Delta-9-THC-induced elevations of mouse-brain tryptophan and consequent increased serotonin production. Pharmacologist 1976, 18:166.
44. Kandel E.R., Spencer W.A. Electrophysiological properties of an archicortical neuron. Ann N Y Acad Sci 1961, 94:570-603.
45. Kelliher P., Connor T.J., Harkin A., Sanchez C., Kelly J.P., Leonard B.E. Varying responses to the rat forced-swim test under diurnal and nocturnal conditions. Physiol Behav 2000, 69:531-539.
46. Laaris N., Good C.H., Lupica C.R. Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 2010, 59(1-2):121-127.
47. Lowry C.A., Rodda J.E., Lightman S.L., Ingram C.D. Corticotropin-releasing factor increases in vitro firing rates of serotonergic neurons in the rat dorsal raphe nucleus: evidence for activation of a topographically organized mesolimbocortical serotonergic system. J Neurosci 2000, 20(20):7728-7736. 15.
48. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159(4):379-387.
49. McPartland J.M., Glass M., Pertwee R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 2007, 152(5):583-593.
50. Mendiguren A., Pineda J. Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. Br J Pharmacol 2009, 158(6):1579-1587.
51. 2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry 2000, 176:182-188.
52. Mitchell P.B., Morris M.J. Depression and anxiety with rimonabant. Lancet 2007, 370(9600):1671-1672.
53. Moldrich G., Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain: an immunohistochemical study. Peptides 2000, 21:1735-1742.
54. Moranta D., Esteban S., Garcia-Sevilla J.A. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:516-524.
55. Moreira F.A., Grieb M., Lutz B. Role of serotonin on the antidepressant-like effect induced by delta-9-tetrahydrocannabinol, but not by rimonabant. 18th Symposium of the International Cannabinoid Research Society, Avemore, Scotland 2008, Abstract, June 25-29.
56. Morrish A.C., Hill M.N., Riebe C.J., Gorzalka B.B. Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission. Physiol Behav 2009, 98(1-2):118-124.
57. Muntoni A.L., Pillolla G., Melis M., Perra S., Gessa G.L., Pistis M. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci 2006, 23(9):2385-2394.
58. Nahas G., Harvey D.J., Sutin K., Turndorf H., Cancro R. A molecular basis of the therapeutic and psychoactive properties of cannabis (Delta(9)-tetrahydrocannabinol). Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:721-730.
59. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P., Myers L., et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008, 1139:434-449.
60. Page M.E., Detke M.J., Dalvi A., Kirby L.G., Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 1999, 147:162-167.
61. Page M.E., Oropeza V.C., Van Bockstaele E.J. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 2008, 431(1):1-5.
62. Palazzo E., de Novellis V., Petrosino S., Marabese I., Vita D., Giordano C., et al. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 2006, 24(7):2011-2020.
63. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic, San Diego.
64. Porsolt R.D., Lepichon M., Jalfre M. Depression - new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
65. Rodríguez-Gaztelumendi A., Rojo M.L., Pazos A., Díaz A. Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 2009, 108(6):1423-1433.
66. Sano K., Mishima K., Koushi E., Orito K., Egashira N., Irie K., et al. Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 2008, 151(2):320-328.
67. Steffens M., Feuerstein T.J. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex-involvement of Na(+)/K(+)-ATPase. Neurochem Int 2004, 44(7):529-538.
68. Steiner M.A., Wotjak C.T. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008, 170:397-432.
69. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003, 138(4):544-553.
70. Urbain N., Creamer K., Debonnel G. Electrophysiological diversity of the dorsal raphe cells across the sleep-wake cycle of the rat. J Physiol 2006, 573:679-695.
71. Valverde O., Torrens M. CB1 receptor-deficient mice as a model for depression. Neuroscience 2012, 204:193-206.
72. Van der Does A.J. The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord 2001, 64(2-3):107-119.
73. Van der Maelen C.P., Aghajanian G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 1983, 289:109-119.
74. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:85-102.
75. Young S.N., Leyton M. The role of serotonin in human mood and social interaction. Insight form altered tryptophan levels. Pharmacol Biochem Behav 2002, 71(4):857-865.
76. Zavitsanou K., Wang H., Dalton V.S., Nguyen V. Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. Neuroscience 2010, 169(1):315-324.
77. Zhu P.J. Endocannabinoid signaling and synaptic plasticity in the brain. Crit Rev Neurobiol 2006, 18(1-2):113-124.
78. Zisook S., Ganadjian K., Moutier C., Prather R., Rao S. Sequenced treatment alternatives to relieve depression (STAR*D): lessons learned. J Clin Psychiatry 2008, 69:1184-1185.